Pneumococcal infections - Pipeline Insight, 2022

Pneumococcal infections - Pipeline Insight, 2022

DelveInsight’s, Pneumococcal infections - Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Pneumococcal infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pneumococcal infections Understanding

Pneumococcal infections: Overview

Streptococcus pneumoniae is a gram-positive, lancet-shaped bacterium and a cause of community-acquired pneumonia. Pneumococcal infections are present throughout the world and are most prevalent during the winter and early spring months. Community-acquired pneumonia (CAP) is the seventh leading cause of death in the United States, and the cost of these hospitalizations is estimated to cost up to $9 billion in the United States (US) dollars each year. Thirty-day hospital mortality associated with CAP has been estimated to be as high as 22% and is the leading cause of death amongst all infectious diseases.

Infection typically occurs after the colonization of the oropharynx and nasopharynx of healthy individuals. Inhalation of these colonies causes the infection of the lower airways. Infection, typically will not result unless a patient has predisposed risk factors, a bolus of infectious cells or due to a particularly virulent strain of S. pneumoniae.

The capsule plays a major role in the pathogenesis of Streptococcus pneumoniae. It is made up of polysaccharides and surrounds the cell wall. It helps in escaping phagocytosis by preventing the access of granulocytes to the underlying cell wall. These polysaccharides of the capsule help in the identification and serotyping of the bacteria. Many serotypes have been detected, 6, 14, 18, 19 and 23 are the most common ones causing the infection. On culture media, the virulence of these strains can be identified by their appearance, opaque and transparent types. Transparent type usually colonizes in nasopharynx while the opaque type is present in the lung, brain and bloodstream infection.

""Pneumococcal infections - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pneumococcal infections pipeline landscape is provided which includes the disease overview and Pneumococcal infections treatment guidelines. The assessment part of the report embraces, in depth Pneumococcal infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pneumococcal infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Pneumococcal infections. The therapies under development are focused on novel approaches to treat/improve Pneumococcal infections.

Pneumococcal infections Emerging Drugs

DWN12088: Daewoong Pharmaceutical

DWN12088 is an investigational therapy for idiopathic pulmonary fibrosis (IPF), that has shown the promising anti-fibrotic properties and appeared to be safe and well-tolerated in a recently-completed Phase I clinical trial that enrolled healthy volunteers. DWN12088 is an investigational IPF therapy that limits the body’s ability to produce collagen by preventing an enzyme called glutamyl-prolyl-tRNA synthetase from adding proline to the protein’s sequence. The FDA designated it as an orphan drug for idiopathic pulmonary fibrosis (IPF) in 2019. The drug is currently in Phase II stage of clinical trial evaluation to treat IPF.

AFX3772: Affinivax

AFX3772, is a lead vaccine candidate targeting Streptococcus pneumoniae, includes 24 pneumococcal polysaccharides, more than any other vaccine on the market, as well as two conserved pneumococcal proteins. Developed using Affinivax’s proprietary MAPS™ (Multiple Antigen-Presenting System) technology platform, AFX3772 is designed to elicit both B-cell (antibody) and T-cell immune protection against Streptococcus pneumoniae. Company expect a Phase III clinical trial in older adults to begin in 2022. The clinical program targeting the infant pneumococcal indication has been initiated with an ongoing Phase 1 study in healthy toddlers 12 to 15 months of age.

PnuBioVax: ImmBio

nuBioVax, a vaccine targeting pneumococcal disease. This project, initiated with funding from the UK’s Biomedical Catalyst, has provided strong evidence of cross-strain efficacy beyond current vaccines. PnuBioVax has now progressed into full Clinical Development with the completion of a Phase I Clinical Trial.

Further product details are provided in the report……..

Pneumococcal infections: Therapeutic Assessment

This segment of the report provides insights about the Pneumococcal infections drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Pneumococcal infections

There are approx. 15+ key companies which are developing the therapies Pneumococcal infections. The companies which have their Pneumococcal infections drug candidates in the most advanced stage, i.e phase II include Affinivax

• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Pneumococcal infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pneumococcal infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pneumococcal infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pneumococcal infections drugs.

Pneumococcal infections Report Insights

• Pneumococcal infections Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pneumococcal infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pneumococcal infections drugs?
• How many Pneumococcal infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pneumococcal infections?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pneumococcal infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pneumococcal infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Merck Sharp & Dohme Corp
• Vaxcyte
• Panacea Biotech
• EuBiologics
• Affinivax
• GangaGen
• ImmBio
• SK bioscience

Key Products

• V 116
• VAX XP
• Pneumococcal vaccine conjugate 10-valent
• ASP 3772
• Pneumococcal conjugate vaccine
• MAPS30
• PnuBioVax
 

Please Note: It will take 7-10 business days to complete the report upon order confirmation.